Eicos Sciences’ Aurlumyn (Iloprost) Receives the US FDA’s Approval for the Treatment of Severe Frostbite
Shots:
- The approval was based on the study evaluating the efficacy of Aurlumyn for treating patients (n=47) with severe frostbite, all received aspirin & SoC. Patients were divided into 3 treatment arms receiving Aurlumyn (IV, 6hrs., daily for up to 8 days) alone in arm 1 & unapproved medications with/without Aurlumyn in arms 2 & 3
- The 1EP was a bone scan taken 7 days post initial frostbite for predicting the need for amputation of at least 1 finger or toe
- The results, on day 7, demonstrated the need for amputation in 0% of patients across arm 1 vs 19% & 60% of them in arms 2 & 3 respectively with a lesser presence of the bone scan abnormality in the groups receiving Aurlumyn
Ref: US FDA | Image: Eicos Sciences
Related News:- Takeda Reports the Results for TAK-861 in P-IIb Trials and Expects to Advance into P-III Trial for the Treatment Narcolepsy Type 1
PharmaShots! Your go-to media platform for customized news ranging for multiple indications. For more information connect with us at connect@pharmashots.com
Click here to read the full press release
Disha is a content writer at PharmaShots. She is passionate and curious about recent updates and developments in MedTech and Pharma industry. She covers news related to clinical trial results and updates. She can be contacted at connect@pharmashots.com.
